SG11202005733QA - Diazaindole compounds - Google Patents
Diazaindole compoundsInfo
- Publication number
- SG11202005733QA SG11202005733QA SG11202005733QA SG11202005733QA SG11202005733QA SG 11202005733Q A SG11202005733Q A SG 11202005733QA SG 11202005733Q A SG11202005733Q A SG 11202005733QA SG 11202005733Q A SG11202005733Q A SG 11202005733QA SG 11202005733Q A SG11202005733Q A SG 11202005733QA
- Authority
- SG
- Singapore
- Prior art keywords
- diazaindole
- compounds
- diazaindole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607941P | 2017-12-20 | 2017-12-20 | |
| PCT/US2018/066108 WO2019126083A1 (en) | 2017-12-20 | 2018-12-18 | Diazaindole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005733QA true SG11202005733QA (en) | 2020-07-29 |
Family
ID=65003573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005733QA SG11202005733QA (en) | 2017-12-20 | 2018-12-18 | Diazaindole compounds |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11299501B2 (en) |
| EP (1) | EP3728264B1 (en) |
| JP (1) | JP7382938B2 (en) |
| KR (1) | KR20200100760A (en) |
| CN (1) | CN111511744B (en) |
| AU (1) | AU2018390544A1 (en) |
| BR (1) | BR112020012002A2 (en) |
| CA (1) | CA3085937A1 (en) |
| EA (1) | EA202091530A1 (en) |
| ES (1) | ES2904773T3 (en) |
| IL (1) | IL275505A (en) |
| MX (1) | MX2020006014A (en) |
| SG (1) | SG11202005733QA (en) |
| WO (1) | WO2019126083A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| CN111491929B (en) * | 2017-12-20 | 2023-11-28 | 百时美施贵宝公司 | Aminoindole compounds useful as TLR inhibitors |
| EA202091479A1 (en) * | 2017-12-20 | 2020-11-24 | Бристол-Маерс Сквибб Компани | ARYL- AND HETEROARYL-SUBSTITUTED INDOL COMPOUNDS |
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| WO2019238616A1 (en) | 2018-06-12 | 2019-12-19 | F. Hoffmann-La Roche Ag | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112584903A (en) | 2018-07-23 | 2021-03-30 | 豪夫迈·罗氏有限公司 | Novel piperazine compounds for the treatment of autoimmune diseases |
| CN112638908A (en) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | Benzothiazoles for treatment of autoimmune diseases |
| JP2022502353A (en) | 2018-09-06 | 2022-01-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | A novel cyclic amidine compound for the treatment of autoimmune disorders |
| WO2022166920A1 (en) * | 2021-02-08 | 2022-08-11 | 杭州中美华东制药有限公司 | Pyrrolopyridazine compound, and preparation method therefor and use thereof |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| WO2023159154A1 (en) * | 2022-02-18 | 2023-08-24 | Bristol-Myers Squibb Company | Substituted imidazopyridinyl compounds useful as inhibitors of tlr9 |
| CN114591339B (en) * | 2022-05-10 | 2022-08-02 | 上海维申医药有限公司 | Toll-like receptor inhibitor and preparation and application thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6867200B1 (en) | 1998-12-18 | 2005-03-15 | Axys Pharmaceuticals, Inc. | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors |
| IL148891A0 (en) | 1999-10-19 | 2002-09-12 | Merck & Co Inc | Tyrosine kinase inhibitors |
| MXPA04006614A (en) | 2002-01-07 | 2004-10-04 | Eisai Co Ltd | Deazapurines and uses thereof. |
| BRPI0411514A (en) | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | small molecule toll-like receptor antagonists |
| WO2006113458A1 (en) | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
| CA2648652A1 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
| DE102006033109A1 (en) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituted heteroaryl derivatives |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| ATE495743T1 (en) | 2006-12-01 | 2011-02-15 | Galapagos Nv | TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF DEGENERATIONAL AND INFLAMMATORY DISEASES |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| WO2009042092A1 (en) | 2007-09-25 | 2009-04-02 | Merck & Co., Inc. | 2-aryl or heteroaryl indole derivatives |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| EP2340243B1 (en) | 2008-10-17 | 2014-10-08 | Boehringer Ingelheim International GmbH | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| TWI462920B (en) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| AU2010273253B2 (en) | 2009-07-16 | 2015-03-12 | Mallinckrodt Llc | (+) - morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof |
| WO2011036130A1 (en) | 2009-09-24 | 2011-03-31 | F. Hoffmann-La Roche Ag | Indole derivatives as crac modulators |
| WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| JP2013166700A (en) * | 2010-06-02 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | Novel 4, 5-fused pyrimidine derivative |
| US9241991B2 (en) | 2010-10-21 | 2016-01-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritus and related skin conditions |
| US20140088085A1 (en) | 2011-01-12 | 2014-03-27 | Array Biopharma, Inc | Substituted Benzoazepines As Toll-Like Receptor Modulators |
| HUE032036T2 (en) | 2011-01-12 | 2017-08-28 | Ventirx Pharmaceuticals Inc | Substituted benzoazepines as toll-like receptor modulators |
| AU2012262021B2 (en) | 2011-06-01 | 2016-07-28 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| WO2012167046A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| IN2014MN00258A (en) | 2011-07-15 | 2015-09-25 | Janssen Pharmaceuticals Inc | |
| JP2013075834A (en) * | 2011-09-29 | 2013-04-25 | Kowa Co | Pyrazolopyrimidine-7-amine derivative exhibiting tlr9-inhibiting activity |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| US20130158040A1 (en) | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | Diazaindole inhibitors of crac |
| CN104302628B (en) | 2012-05-18 | 2017-06-23 | 大日本住友制药株式会社 | Carboxylic acid compound |
| JO3407B1 (en) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | Tetrahydropyrazolopyrimidine Compounds |
| US9388185B2 (en) * | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| WO2015057659A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| CA2933466A1 (en) | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| UA117634C2 (en) | 2014-08-15 | 2018-08-27 | Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. | Pyrrolopyrimidine compounds used as tlr7 agonist |
| US20170275287A1 (en) | 2014-08-22 | 2017-09-28 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| US10071079B2 (en) * | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| US11180474B2 (en) | 2016-07-30 | 2021-11-23 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
| ES2902504T3 (en) | 2016-09-09 | 2022-03-28 | Bristol Myers Squibb Co | Pyridyl Substituted Indole Compounds |
| EP3710440B1 (en) * | 2017-11-14 | 2023-04-05 | Bristol-Myers Squibb Company | Substituted indole compounds |
| CA3085817A1 (en) * | 2017-12-18 | 2019-06-27 | Bristol-Myers Squibb Company | 4-azaindole compounds |
| EP3728253B1 (en) * | 2017-12-19 | 2024-03-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
-
2018
- 2018-12-18 SG SG11202005733QA patent/SG11202005733QA/en unknown
- 2018-12-18 MX MX2020006014A patent/MX2020006014A/en unknown
- 2018-12-18 EA EA202091530A patent/EA202091530A1/en unknown
- 2018-12-18 CA CA3085937A patent/CA3085937A1/en active Pending
- 2018-12-18 ES ES18830674T patent/ES2904773T3/en active Active
- 2018-12-18 KR KR1020207020851A patent/KR20200100760A/en not_active Application Discontinuation
- 2018-12-18 JP JP2020534861A patent/JP7382938B2/en active Active
- 2018-12-18 BR BR112020012002-2A patent/BR112020012002A2/en not_active Application Discontinuation
- 2018-12-18 WO PCT/US2018/066108 patent/WO2019126083A1/en unknown
- 2018-12-18 CN CN201880082762.7A patent/CN111511744B/en active Active
- 2018-12-18 AU AU2018390544A patent/AU2018390544A1/en not_active Abandoned
- 2018-12-18 EP EP18830674.0A patent/EP3728264B1/en active Active
- 2018-12-18 US US16/955,108 patent/US11299501B2/en active Active
-
2020
- 2020-06-18 IL IL275505A patent/IL275505A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111511744A (en) | 2020-08-07 |
| AU2018390544A1 (en) | 2020-08-06 |
| US20200308195A1 (en) | 2020-10-01 |
| KR20200100760A (en) | 2020-08-26 |
| WO2019126083A1 (en) | 2019-06-27 |
| EP3728264B1 (en) | 2021-12-01 |
| EA202091530A1 (en) | 2020-09-14 |
| ES2904773T3 (en) | 2022-04-06 |
| JP7382938B2 (en) | 2023-11-17 |
| US11299501B2 (en) | 2022-04-12 |
| IL275505A (en) | 2020-08-31 |
| MX2020006014A (en) | 2020-08-17 |
| JP2021506941A (en) | 2021-02-22 |
| EP3728264A1 (en) | 2020-10-28 |
| CA3085937A1 (en) | 2019-06-27 |
| CN111511744B (en) | 2023-09-22 |
| BR112020012002A2 (en) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201708456D0 (en) | Senolytic compounds | |
| GB201704327D0 (en) | Compounds | |
| GB201700814D0 (en) | Compounds | |
| IL275505A (en) | Diazaindole compounds | |
| GB201704325D0 (en) | Compounds | |
| GB201715342D0 (en) | Compounds | |
| GB201713962D0 (en) | Compounds | |
| IL292485B2 (en) | Pyridylpyridone compounds | |
| GB201717051D0 (en) | Compounds | |
| GB201716871D0 (en) | Compounds | |
| GB201707938D0 (en) | Compounds | |
| GB201706162D0 (en) | Compounds | |
| GB201715786D0 (en) | Compounds | |
| GB201707856D0 (en) | Compounds | |
| GB201702221D0 (en) | Compounds | |
| GB201716369D0 (en) | Compounds | |
| GB201703282D0 (en) | Compounds | |
| GB201721331D0 (en) | Compounds | |
| GB201721326D0 (en) | Compounds | |
| GB201721330D0 (en) | Compounds | |
| GB201720495D0 (en) | ß-lactone compounds | |
| GB201720064D0 (en) | Compounds | |
| GB201719261D0 (en) | Compounds | |
| GB201717718D0 (en) | Compounds | |
| GB201717050D0 (en) | Compounds |